Peptide hormone · therapeutic protein family
Insulin
A natural peptide hormone and foundational family of diabetes medicines whose effects, risks, and use depend on the exact product and care plan.
Also known as human insulin · insulin analogue · rapid-acting insulin · basal insulin
01 · Evidence profile
One molecule, four evidence questions
Long-term randomized evidence supports monitored insulin strategies for defined diabetes populations.
Product-specific onset, peak, duration, and exposure are extensively characterized.
Labels and decades of clinical use characterize major risks, especially hypoglycemia.
High for an authentic approved product; the exact product and formulation still matter.
02 · Identity
What it is
Insulin is a hormone made by the pancreas and the name used for a family of biologic medicines. Rapid-acting, short-acting, intermediate-acting, long-acting, and mixed products have different profiles, so the broad word “insulin” is not a complete product description.
03 · Product identity
The molecule is not the finished product.
Insulin names cover multiple approved biologic products with different concentrations, time-action profiles, delivery systems, and labels.
Humalog
2025 label- Formulation
- Multiple product-specific concentrations and delivery presentations
- Route
- Subcutaneous; intravenous use is product- and setting-specific
- Indication scope
- Diabetes treatment in the populations and uses defined by the current Humalog prescribing information; this representative record does not describe every insulin product.
- Multiple human insulin and insulin analogue products
- Diabetes treatment in product-specific labeled populations
04 · Evidence snapshot
What the evidence can and cannot say
Insulin replacement is essential for people with type 1 diabetes and is also used in other forms of diabetes. In the Diabetes Control and Complications Trial, an intensive monitored strategy reduced the development and progression of several long-term complications in people with type 1 diabetes. The same program also documented more severe hypoglycemia, showing why benefit and risk have to be managed together.
There is no universal insulin product, schedule, target, or intensity that is right for every person. Evidence for one formulation, population, or monitored strategy does not justify free substitution, unsupervised changes, or non-medical use.
05 · Claim check
Three claims under the lens
“Insulin is an established treatment for diabetes.”
Multiple insulin products are FDA-approved, and long-term human evidence supports insulin strategies in defined diabetes populations. The exact product and care context still matter.
- Evidence basis
- Randomized human outcomes
- Scope
- FDA-approved insulin products and monitored treatment strategies in defined diabetes populations.
“All insulin products work the same way and can be swapped freely.”
Insulin products differ in timing, concentration, delivery system, and approved labeling. A switch can require clinical oversight and product-specific instructions.
- Evidence basis
- Regulatory or product record
- Scope
- Product-specific insulin formulations, concentrations, delivery systems, and labels.
“More intensive insulin treatment is always better.”
The DCCT found important complication reductions alongside substantially more severe hypoglycemia. Treatment intensity must be individualized and monitored.
- Evidence basis
- Randomized human outcomes
- Scope
- The monitored intensive-treatment strategy and type 1 diabetes population studied in the DCCT.
06 · Safety boundary
Before this becomes personal
Hypoglycemia can be severe and life-threatening. Product mix-ups and unsupervised switches are high-stakes. This guide does not provide dose calculations, correction factors, injection technique, or advice for changing an insulin plan.
Insulin is prohibited under the current WADA hormone and metabolic modulator framework unless an applicable therapeutic-use exemption authorizes use.
Reviewed 2026-07-23. This status is not personal clearance to compete.Check the governing record ↗07 · Sources
Check the primary record
08 · Provenance
Review history
Expanded product-family, safety, and claim provenance fields.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.